Composite outcomes in clinical trials: what are they and when should they be used?

被引：11
|
作者：
Heddle, Nancy M.
Cook, Richard J.
机构：
[1] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada
[2] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada
来源：
TRANSFUSION | 2011年 / 51卷 / 01期
关键词：
RANDOMIZED CONTROLLED-TRIAL; PREMATURE-INFANTS; END-POINTS; TRANSFUSION; STRATEGIES;
D O I：
10.1111/j.1537-2995.2010.02930.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [31] Outcomes measures used in clinical trials in neuromuscular diseases
    Boussaid, Ghilas
    Vuillerot, Carole
    Domingos, Joana Pisco
    Dany, Antoine
    Ricci, Enzo
    Servais, Laurent
    Boyer, Francois Constant
    M S-MEDECINE SCIENCES, 2018, 34 : 49 - 50
  • [32] CLINICAL-TRIALS OF RADIOSENSITIZERS - WHAT SHOULD WE EXPECT
    BROWN, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (03): : 425 - 429
  • [33] What Should Be Done About Bias and Misconduct in Clinical Trials?
    Fairman, Kathleen A.
    Curtiss, Frederic R.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (02): : 154 - 160
  • [34] Major clinical trials of hypertension - What should be done next?
    Alderman, MH
    Arnett, DK
    Bakris, GL
    Black, HR
    Boerwinkle, E
    Califf, RM
    Cushman, WC
    Cutler, J
    Davis, BR
    Devereux, RB
    Ferdinand, K
    Fleg, JL
    Fournier, A
    Furberg, CD
    Giles, TD
    Gottdiener, JS
    Grimm, RH
    Hyman, DJ
    Jamerson, KA
    Kostis, JB
    Krauss, RM
    Leenen, FHH
    Levey, AS
    Levy, D
    MacMahon, S
    Oparil, S
    Probstfield, JL
    Psaty, BM
    Roccella, E
    Salive, M
    Schwartz, WB
    Svetkey, L
    Throckmorton, D
    Turner, ST
    Velletri, P
    Wright, J
    HYPERTENSION, 2005, 46 (01) : 1 - 6
  • [35] What should be the ideal design of phase I clinical trials?
    Lau, Derick
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S76 - S76
  • [36] What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?
    Grill, Joshua D.
    Sperling, Reisa A.
    Raman, Rema
    JAMA NEUROLOGY, 2022, 79 (11) : 1097 - 1098
  • [37] When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts
    Jakobsen, Janus Christian
    Gluud, Christian
    Wetterslev, Jorn
    Winkel, Per
    BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [38] When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
    Janus Christian Jakobsen
    Christian Gluud
    Jørn Wetterslev
    Per Winkel
    BMC Medical Research Methodology, 17
  • [39] The fragility index should not be used for sample size calculations in clinical trials
    Potter, Gail E.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 142 : 315 - 316
  • [40] WHEN SHOULD GRASS BE USED
    BRADLEY, WG
    RADIOLOGY, 1988, 169 (02) : 574 - 575
12345